This inspection is the fourth major regulatory inspection (after Russia, Canada and Brazil), cleared by this site in the past two years
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
Lupin enters into BTA with Lupin Manufacturing Solutions
He has 37 years of experience in API Intermediaries, Pharma and Chemicals industr
Prateek has more than 23 years of rich experience in Human Resource
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
The new gummy capabilities include a dedicated R&D lab, an automated production line, and bottle packaging solutions
Subscribe To Our Newsletter & Stay Updated